The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study.
Salomon M. Stemmer
Stock Ownership - Can-Fite BioPharma
Ofer Benjaminov
No relevant relationships to disclose
Gal Medalia
No relevant relationships to disclose
Noa Ciuraru
No relevant relationships to disclose
Michael H. Silverman
Consultant or Advisory Role - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Sara Bar Yehuda
Stock Ownership - Can Fite BioPharma
Sari Fishman
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Zivit Harpaz
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Motti Farbstein
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Shira Cohen
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Renana Petoka
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Barak Singer
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
William D Kerns
Consultant or Advisory Role - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma
Pnina Fishman
Employment or Leadership Position - Can Fite BioPharma
Stock Ownership - Can Fite BioPharma